Apellis Pharmaceuticals, Inc.
We Are Apellis
We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
For more information on our company and science, please visit https://apellis.com/.
To learn more about the ongoing burden of hemolysis experienced by PNH patients despite the clinical improvements seen with current treatments, please visit https://understandingpnh.com/.
©2021 Apellis Pharmaceuticals, Inc. All rights reserved. 1/21 US-PNH-2100008 v1.0